## Edgar Filing: TRANSGENOMIC INC - Form 8-K

## TRANSGENOMIC INC

Form 8-K January 21, 2004

\_\_\_\_\_\_

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
January 20, 2004

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Delaware (State of Formation)

000-30975 (Commission File Number)

911789357

(IRS Employer Identification Number)

12325 Emmet Street

Omaha, NE

68164

(Address of principal executive offices)

(Zip Code)

(402) 452-5400

(Registrants' telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

\_\_\_\_\_\_

Item 5. Other Events and Regulation FD Disclosure.

On January 20, 2004, the Company issued a press release announcing it has entered into an agreement with SpectruMedix LLC to distribute its RevealTM Genetic Analysis Systems in Europe. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

- (c) Exhibits
- 99.1 Press Release, dated January 20, 2004, announcing that the Company has entered into an agreement with SpectruMedix LLC to distribute its RevealTM Genetic Analysis Systems in Europe.

2

## Edgar Filing: TRANSGENOMIC INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Michael J. Draper

\_\_\_\_\_

Michael J. Draper, Chief Financial Officer

January 20, 2004

3